Lenalidomide demonstrates clinical activity in anaplastic lymphoma kinase-positive large B-cell lymphoma

Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+ LBCL) is known to be a rare and aggressive form of lymphoma that relapses quickly after both conventional chemotherapy and more targeted therapy. Lenalidomide is an immunomodulator that has shown safety and efficacy in multiple myeloma...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMJ Case Rep
Hauptverfasser: Bhaskar, Shakthi, Abro, Brooj, Fraum, Tyler J, Mehta-Shah, Neha
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMJ Publishing Group 2020
Schlagworte:
Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation)
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7449333/
https://ncbi.nlm.nih.gov/pubmed/32843459
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2020-235578
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge